About Aragen Life Sciences
Aragen Life Sciences is a company based in Hyderabad (India) founded in 2001. It operates as a Professional Services and Managed Services. Aragen Life Sciences has raised $195.65 million across 5 funding rounds from investors including Goldman Sachs, Avendus and Quadria Capital. The company has 3,859 employees as of April 08, 2024. Aragen Life Sciences has completed 3 acquisitions, including Aragen Bioscience, INTOX lab and Vanta Bioscience. Aragen Life Sciences offers products and services including Small Molecules and Large Molecules (Biologics). Aragen Life Sciences operates in a competitive market with competitors including Hybio Pharmaceutical, Nephron Pharmaceuticals, Suanfarma, Aiolos Bio and Kardigan, among others.
- Headquarter Hyderabad, India
- Employees 3859 as on 08 Apr, 2024
- Stage Minicorn
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Aragen Life Sciences Ltd.
- Jurisdiction Hyderabad, Telangana, India
-
Annual Revenue
$195.64 M (USD)-4.42as on Mar 31, 2024
-
Net Profit
$18.7 M (USD)-27.18as on Mar 31, 2024
-
EBITDA
$50.54 M (USD)-13.01as on Mar 31, 2024
-
Total Equity Funding
$195.65 M (USD)
in 5 rounds
-
Latest Funding Round
$36 M (USD), Private Equity Round
Aug 13, 2025
-
Investors
Goldman Sachs
& 3 more
-
Employee Count
3859
as on Apr 08, 2024
-
Investments & Acquisitions
Aragen Bioscience
& 2 more
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Aragen Life Sciences
Aragen Life Sciences offers a comprehensive portfolio of products and services, including Small Molecules and Large Molecules (Biologics).
Small molecules are developed and manufactured for pharmaceuticals.
Biologics solutions are provided from gene to clinic.
People of Aragen Life Sciences
Unlock access to complete
Unlock access to complete
Leadership Team
51 people
Senior Team
27 people
Software Development Team
24 people
Associate Team
20 people
Sales and Marketing
20 people
Scientific Team
19 people
Principal Team
18 people
Human Resources and Administration
13 people
Unlock access to complete
Funding Insights of Aragen Life Sciences
Aragen Life Sciences has successfully raised a total of $195.65M across 5 strategic funding rounds. The most recent funding activity was a Private Equity Round of $36 million completed in August 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Aragen Life Sciences
Aragen Life Sciences has secured backing from 4 investors, including venture fund and institutional investors. Prominent investors backing the company include Goldman Sachs, Avendus and Quadria Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Healthcare private equity investments focused on Asian markets.
|
Locked | Locked | Locked | |
|
Investment banking services are delivered across multiple financial sectors.
|
Locked | Locked | Locked | |
|
Sequoia Capital is engaged in venture capital investments.
|
Locked | Locked | Locked |
Investor details for Aragen Life Sciences
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Aragen Life Sciences
Aragen Life Sciences has strategically engaged in corporate development activities, having acquired 3 companies. Notable acquisitions include Aragen Bioscience, INTOX lab and Vanta Bioscience.
Investment portfolio details for Aragen Life Sciences
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
GLP-certified preclinical contract research services are provided.
|
Locked | Locked | 2010 | Locked | |
|
Preclinical contract research services in toxicology are offered.
|
Locked | Locked | 1995 | Locked | |
|
CRO offering cell line development, protein and antibody production, in vivo models of human disease and safety studies.
|
Locked | Locked | 1993 | Locked |
Complete acquisition details for Aragen Life Sciences
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - Aragen Life Sciences
Detailed financials for Aragen Life Sciences
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Aragen Life Sciences Comparisons
Peer comparison for Aragen Life Sciences
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Aragen Life Sciences
Aragen Life Sciences operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Hybio Pharmaceutical, Nephron Pharmaceuticals, Suanfarma, Aiolos Bio and Kardigan, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Polypeptide drugs and APIs are developed and manufactured.
|
|
| Locked | Locked | Locked |
Sterile pharmaceutical products are manufactured and contract services are provided.
|
|
| Locked | Locked | Locked |
Generics, nutraceuticals, and APIs are developed by Suanfarma.
|
|
| Locked | Locked | Locked |
Biotech company focused on developing innovative therapies for respiratory diseases and immune conditions
|
|
| Locked | Locked | Locked |
Biotech company developing personalized medicines for cardiovascular diseases
|
|
| Locked | Locked | Locked |
CDMO and analytical services for peptide development are provided.
|
Detailed competitors of Aragen Life Sciences
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Aragen Life Sciences
Complete news archive for Aragen Life Sciences
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Aragen Life Sciences
Aragen Life Sciences was founded in 2001 and raised its 1st funding round 6 years after it was founded.
Aragen Life Sciences is headquartered in Hyderabad, India. It is registered at Hyderabad, Telangana, India.
Manni Kantipudi is the current CEO of Aragen Life Sciences.
Aragen Life Sciences is a funded company, having raised a total of $195.65M across 5 funding rounds to date.
As of Apr 08, 2024, the latest employee count at Aragen Life Sciences is 3,859.
Annual revenue of Aragen Life Sciences is $195.64M as on Mar 31, 2024.
Aragen Life Sciences is involved in providing contract research, development, and manufacturing solutions for the pharmaceutical and biotech industries. Services are offered in small molecules and large molecules (biologics), covering discovery, development, and production. Operations are conducted across multiple global locations in Asia, North America, and Europe. Innovative solutions are delivered to support clients from concept to commercial stages. A focus is maintained on quality, sustainability, and intellectual property protection.
Aragen Life Sciences's top competitors include Nephron Pharmaceuticals, Suanfarma and Hybio Pharmaceutical.
Aragen Life Sciences offers Small Molecules and Large Molecules (Biologics).
Aragen Life Sciences has made 3 acquisitions, including Aragen Bioscience, INTOX lab, and Vanta Bioscience.
Aragen Life Sciences has 4 investors. Key investors include Goldman Sachs, Avendus, Quadria Capital, and Sequoia Capital.
The valuation of Aragen Life Sciences is $272.82M as of Nov 2007.